Key Insights on Gross Profit: GSK plc vs Supernus Pharmaceuticals, Inc.

GSK vs Supernus: A Decade of Gross Profit Insights

__timestampGSK plcSupernus Pharmaceuticals, Inc.
Wednesday, January 1, 201415683000000116287000
Thursday, January 1, 201515070000000136004000
Friday, January 1, 201618599000000203017000
Sunday, January 1, 201719844000000287023000
Monday, January 1, 201820580000000393541000
Tuesday, January 1, 201921891000000376095000
Wednesday, January 1, 202022395000000467938000
Friday, January 1, 202122511000000504714000
Saturday, January 1, 202219770000000580017000
Sunday, January 1, 202321763000000523742000
Loading chart...

Igniting the spark of knowledge

A Decade of Gross Profit: GSK plc vs Supernus Pharmaceuticals, Inc.

In the ever-evolving pharmaceutical industry, understanding financial performance is crucial. Over the past decade, GSK plc has consistently outperformed Supernus Pharmaceuticals, Inc. in terms of gross profit. From 2014 to 2023, GSK's gross profit surged by approximately 39%, peaking at over $22 billion in 2021. In contrast, Supernus Pharmaceuticals, Inc. experienced a remarkable growth of over 350% during the same period, albeit from a much smaller base, reaching around $580 million in 2022.

This stark contrast highlights the scale and market reach differences between the two companies. While GSK's growth is steady, Supernus's rapid increase reflects its aggressive expansion strategy. As the pharmaceutical landscape continues to shift, these insights provide a glimpse into the strategic maneuvers of industry giants and emerging players alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025